114 related articles for article (PubMed ID: 23419368)
1. Multiple sclerosis: T-cell resistance to regulation in RRMS linked to IL-6 pathway.
Malpass K
Nat Rev Neurol; 2013 Mar; 9(3):122. PubMed ID: 23419368
[No Abstract] [Full Text] [Related]
2. In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T(regs) involves IL-6-mediated signaling.
Schneider A; Long SA; Cerosaletti K; Ni CT; Samuels P; Kita M; Buckner JH
Sci Transl Med; 2013 Jan; 5(170):170ra15. PubMed ID: 23363979
[TBL] [Abstract][Full Text] [Related]
3. Altered frequency of T regulatory cells is associated with disability status in relapsing-remitting multiple sclerosis patients.
Bjerg L; Brosbøl-Ravnborg A; Tørring C; Dige A; Bundgaard B; Petersen T; Höllsberg P
J Neuroimmunol; 2012 Aug; 249(1-2):76-82. PubMed ID: 22608884
[TBL] [Abstract][Full Text] [Related]
4. miR-27a and miR-214 exert opposite regulatory roles in Th17 differentiation via mediating different signaling pathways in peripheral blood CD4+ T lymphocytes of patients with relapsing-remitting multiple sclerosis.
Ahmadian-Elmi M; Bidmeshki Pour A; Naghavian R; Ghaedi K; Tanhaei S; Izadi T; Nasr-Esfahani MH
Immunogenetics; 2016 Jan; 68(1):43-54. PubMed ID: 26563334
[TBL] [Abstract][Full Text] [Related]
5. CD28 ligation in the absence of TCR stimulation up-regulates IL-17A and pro-inflammatory cytokines in relapsing-remitting multiple sclerosis T lymphocytes.
Camperio C; Muscolini M; Volpe E; Di Mitri D; Mechelli R; Buscarinu MC; Ruggieri S; Piccolella E; Salvetti M; Gasperini C; Battistini L; Tuosto L
Immunol Lett; 2014; 158(1-2):134-42. PubMed ID: 24412596
[TBL] [Abstract][Full Text] [Related]
6. Regulatory T cells fail to suppress CD4T+-bet+ T cells in relapsing multiple sclerosis patients.
Frisullo G; Nociti V; Iorio R; Patanella AK; Caggiula M; Marti A; Sancricca C; Angelucci F; Mirabella M; Tonali PA; Batocchi AP
Immunology; 2009 Jul; 127(3):418-28. PubMed ID: 19016907
[TBL] [Abstract][Full Text] [Related]
7. Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism.
Ramos-Cejudo J; Oreja-Guevara C; Stark Aroeira L; Rodriguez de Antonio L; Chamorro B; Diez-Tejedor E
J Clin Immunol; 2011 Aug; 31(4):623-31. PubMed ID: 21491095
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Soluble Human Leukocyte Antigen-G (sHLA-G) Isoforms and Regulatory T Cells in Relapsing-Remitting Multiple Sclerosis.
Alsahebfosoul F; Zavaran Hosseini A; Salehi R; Etemadifar M; Esmaeil N; Jamshidian A
Iran J Allergy Asthma Immunol; 2015 Jun; 14(3):298-305. PubMed ID: 26546899
[TBL] [Abstract][Full Text] [Related]
9. Regulatory Cell Populations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: Effect of Disease Activity and Treatment Regimens.
Rodi M; Dimisianos N; de Lastic AL; Sakellaraki P; Deraos G; Matsoukas J; Papathanasopoulos P; Mouzaki A
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27571060
[TBL] [Abstract][Full Text] [Related]
10. The T-cell pool is anergized in patients with multiple sclerosis in remission.
Fransson ME; Liljenfeldt LS; Fagius J; Tötterman TH; Loskog AS
Immunology; 2009 Jan; 126(1):92-101. PubMed ID: 18624727
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the relationship between leptin, resistin, adiponectin and natural regulatory T cells in relapsing-remitting multiple sclerosis.
Kraszula L; Jasińska A; Eusebio M; Kuna P; Głąbiński A; Pietruczuk M
Neurol Neurochir Pol; 2012; 46(1):22-8. PubMed ID: 22426759
[TBL] [Abstract][Full Text] [Related]
12. Deferiprone modulates in vitro responses by peripheral blood T cells from control and relapsing-remitting multiple sclerosis subjects.
Sweeney ME; Slusser JG; Lynch SG; Benedict SH; Garcia SL; Rues L; LeVine SM
Int Immunopharmacol; 2011 Nov; 11(11):1796-801. PubMed ID: 21807124
[TBL] [Abstract][Full Text] [Related]
13. Fine-tuning the homeostasis of regulatory T cells: new mechanism of immunomodulatory therapy in multiple sclerosis.
Hofstetter HH; Stüve O; Hartung HP
Arch Neurol; 2008 Nov; 65(11):1417-8. PubMed ID: 19001158
[No Abstract] [Full Text] [Related]
14. Identification of T helper type 1-like, Foxp3+ regulatory T cells in human autoimmune disease.
Dominguez-Villar M; Baecher-Allan CM; Hafler DA
Nat Med; 2011 Jun; 17(6):673-5. PubMed ID: 21540856
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Regulatory T-Cells in Multiple Sclerosis Patients Treated with Interferon Beta-1a.
Ebrahimimonfared M; Ganji A; Zahedi S; Nourbakhsh P; Ghasami K; Mosayebi G
CNS Neurol Disord Drug Targets; 2018; 17(2):113-118. PubMed ID: 29589548
[TBL] [Abstract][Full Text] [Related]
16. CD127 immunophenotyping suggests altered CD4+ T cell regulation in primary progressive multiple sclerosis.
McKay FC; Swain LI; Schibeci SD; Rubio JP; Kilpatrick TJ; Heard RN; Stewart GJ; Booth DR
J Autoimmun; 2008 Aug; 31(1):52-8. PubMed ID: 18406576
[TBL] [Abstract][Full Text] [Related]
17. [Relapsing-remitting multiple sclerosis: clinical and immunological aspects of the pathology on the example Sema4D and CD72].
Danchenko IY; Baidina TV; Kuklina EM; Trushnikova TN; Nekrasova IV
Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(10. Vyp. 2):63-71. PubMed ID: 31934990
[TBL] [Abstract][Full Text] [Related]
18. Role of IL-16 in CD4+ T cell-mediated regulation of relapsing multiple sclerosis.
Skundric DS; Cruikshank WW; Drulovic J
J Neuroinflammation; 2015 Apr; 12():78. PubMed ID: 25896927
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis.
Smolders J; Thewissen M; Peelen E; Menheere P; Tervaert JW; Damoiseaux J; Hupperts R
PLoS One; 2009 Aug; 4(8):e6635. PubMed ID: 19675671
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory function of Treg-derived exosomes is impaired in patients with relapsing-remitting multiple sclerosis.
Azimi M; Ghabaee M; Moghadasi AN; Noorbakhsh F; Izad M
Immunol Res; 2018 Aug; 66(4):513-520. PubMed ID: 29882035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
